Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naureckas, E. T.
Right arrow Articles by Rathouz, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naureckas, E. T.
Right arrow Articles by Rathouz, P.
(Chest. 2005;128:602-608.)
© 2005 American College of Chest Physicians

Short-Acting ß-Agonist Prescription Fills as a Marker for Asthma Morbidity*

Edward T. Naureckas, MD, FCCP; Vanja Dukic, PhD; Xiaoming Bao, MSc and Paul Rathouz, PhD

* From the Departments of Medicine, Health Studies, and Department of Statistics, University of Chicago, Chicago, IL.

Correspondence to: Edward T. Naureckas, MD, FCCP, Associate Professor of Medicine, University of Chicago, 5841 South Maryland Ave, MC 6076, Chicago, IL 60637; e-mail: tnaureka{at}medicine.bsd.uchicago.edu

Objectives: Hospital admissions and emergency department (ED) visits have traditionally been used to assess the strength of association between environmental exposures, such as air pollution, and asthma morbidity. In the current study, we evaluate the use of short-acting ß-agonist (SABA) prescriptions as a surrogate marker for asthma exacerbation with respect to these more traditional markers.

Methods: Claims data for recipients covered by Illinois Medicaid with a diagnosis of asthma were obtained for fiscal-years 1996 through June 1998. Claims for short-acting bronchodilators and asthma-related ED visits and hospital admissions for 31,140 adults were identified. The odds ratio for the association of either an ED visit or hospital admission and an SABA prescription was calculated for time lags ranging from – 28 to + 28 days. Individual-subject heterogeneity and seasonal effects were corrected for using the Mantel-Haenszel method.

Results: After adjustment for individual and seasonal effects, there was a significant positive association between SABA prescriptions and ED visits or hospital admissions for asthma on any single day. In addition, a significant positive association was also found between the ED visits or hospital admissions occurring on the few days prior to an SABA prescription. No significant relation was found (after adjusting for subject and seasonal effects) between prescriptions and admissions when an SABA prescription date preceded that of a hospital admission or an ED visit.

Conclusions: A very strong and significant association between ED visits or hospital admissions for asthma and SABA prescriptions was observed, which suggests that SABA prescription fills can be used as a marker for asthma morbidity. In addition, a temporal association exists between claims for ED visits or hospital admissions for asthma and SABA prescription claims when an ED visit or hospital admission precedes the SABA prescription.

Key Words: administrative database • asthma • asthma emergency department visits • asthma hospitalizations • asthma outcomes • ß-agonists






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.